Second-line chemotherapy in head and neck cancer: what should we expect?

Büntzel, Jens; Micke, Oliver

doi:10.1586/14737140.9.3.269

Cited by 5 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nivolumab recruits tumor-infiltrating lymphocytes and upregulates interferon-γ-related chemokines, independent of nivolumab-treatment status. 8 Platin salts (in particular cisplatin) immunomodulatory effect include 1 major histocompatibility complex (MHC) class I expression upregulation, 2 recruitment and proliferation of effector cells, 3 upregulation of the lytic activity of cytotoxic effectors, 4 and downregulation of the immunosuppressive microenvironment. 9 Moreover, both platin salts and taxans are known to decrease the number of regulatory T cells (Tregs) and restore the antitumor activity of CD8+ cells (Teff ).…”

Section: Discussionmentioning

confidence: 99%

“…2 Methotrexate, taxans, and cetuximab monotherapy (in United States) were sometimes used following platinum failure or in patients not fit enough for platinum therapy, but these agents have not demonstrated any OS improvement. 3 Until the publication of the results of CheckMate 141, not a single agent provided any survival benefit as a second-line treatment for recurrent or metastatic HNSCC. Nivolumab confers an OS benefit as compared to standard care (single-agent docetaxel, methotrexate, or cetuximab).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Unexpected response with palliative conventional therapy in head and neck squamous cell carcinoma after anti‐programmed death‐1 progression

Denaro

Merlano

2019

Head & Neck

View full text Add to dashboard Cite

Background The application of anti‐programmed death‐1 (PD‐1) therapies for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) has found promising results. It is the first “second‐line therapy” in this setting to impact on prognosis. The studies demonstrated overall response rates in the range of 20%. Therefore, HNSCC showed 60%‐80% progression at first evaluation with better overall survival, suggesting regained efficacy of treatments given thereafter. Methods We report three clinical cases treated with anti‐PD‐1 after platinum‐based chemotherapy. Results Our case reports achieved an unforeseen response to conventional therapies supporting the hypothesis of restored responses to conventional therapies after immunotherapy. Conclusions We believe that the inhibition of the PD‐1/PD‐ligand 1 checkpoint may synergize with both chemotherapy or radiotherapy through immunologic interplay, reversing the HNSCC‐induced immune suppression.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Unexpected response with palliative conventional therapy in head and neck squamous cell carcinoma after anti‐programmed death‐1 progression

Denaro

Merlano

2019

Head & Neck

View full text Add to dashboard Cite

show abstract

“…No standard second line of treatment has been established [66]. Some studies have been performed in the second line involving the continuation of cetuximab in platinum-refractory patients who have already received anti-EGFR antibodies.…”

Section: Recurrent or Metastatic Hnsccmentioning

confidence: 99%

“…Several agents (such as vinorelbine, docetaxel, methotrexate) have shown to be effective in the second-line treatment for these patients but overall RR are lower than 15% [66]. For second-line treatment, many authors consider re-challenge with platinum in patients with a good performance, using a combination with a taxane or 5-FU.…”

Section: Recurrent or Metastatic Hnsccmentioning

confidence: 99%

“…The most-studied mAbs include cetuximab (already approved for the treatment of LA-HNSCC [12] or for the first-line treatment of R/M-HNSCC in combination with platinum-based CT [65] and/or as a single agent for the treatment of patients with R/M-HNSCC for whom prior platinum-based therapy has failed [66]) and panitumumab (Pmab), which is a fully humanized EGFR inhibitor. Like cetuximab, it was also investigated in a phase III study (the SPECTRUM) for the first-line treatment of R/M-HNSCC, for which Pmab in combination with 5-FU plus P was compared to PF alone.…”

Section: Recurrent or Metastatic Hnsccmentioning

confidence: 99%

See 1 more Smart Citation

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Denaro¹,

Russi

Adamo

et al. 2014

Oncology

View full text Add to dashboard Cite

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cause of cancer death worldwide. Its treatment is complex and evolving. In general, early-stage disease may be managed with single-modality treatment while an advanced stage (about 60% of clinical presentation) needs a multidisciplinary approach. In this setting concurrent chemoradiation has been associated with improvement in locoregional control and organ preservation, but at the cost of significant acute and chronic toxicity. Molecular target therapies specially directed to epidermal growth factor receptor (EGFR) might improve the outcomes and reduce toxicities. In recurrent-metastatic (R/M) HNSCC, cetuximab, a monoclonal antibody against EGFR, plus platinum-based chemotherapy (CT) allow an overall survival (OS) of about 10 months. However, the prognosis for R/M-HNSCC remains dismal and additional efforts are needed. At the 2013 American Society of Clinical Oncology (ASCO) Meeting, data on induction CT, anti-EGFR inhibitors, innovative molecular targets and predictor factors were reported. Further results on target therapies were presented at the European Cancer Congress (ECC) 2013, where a large study also showed that hyperfractionated radiotherapy (RT) improve OS rates compared with standard RT. The aim of this review is to discuss current standards and emerging therapies by considering recent new updates.

show abstract

Real-world Data of Paclitaxel and Cetuximab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Aguín

Carral

Iglesias

et al. 2023

CDP

View full text Add to dashboard Cite

Background/Aim: Prior immune-checkpoint inhibitors, weekly paclitaxel-cetuximab was one of the few options for platinum-ineligible patients with recurrent/ metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN). This real-world study analyzed the long-term outcomes of this regimen. Patients and Methods: A multicenter, retrospective, observational, cross-sectional, chart review study was realized in nine hospitals of the Galician Group of Head and Neck Cancer. Eligible population was adult platinum-ineligible patients with R/M SCCHN (unfit to, or after progressing following EXTREME or other platinum-based regimens) that received weekly paclitaxel plus cetuximab regimen as first- or second-line (1L or 2L) between January 2009 and December 2014. The efficacy was evaluated (1L-2L) in regards to overall survival (OS) and progression-free survival (PFS), and safety was assessed as the incidence of adverse events (AEs). Results: Seventy-five R/M-SCCHN patients received the scheme (1L, n=50; 2L: n=25). The mean age of the patients was 59 years (1L, 59.5 years; 2L, 59.2 years), 90% were male (1L, 96%; 2L, 79%), 55% were smokers (1L, 60.4%; 2L, 45.8%), and 61% presented ECOG performance status (PS) 1 (1L, 54%; 2L, 62.5%). Median OS [interquartile range (IQR)] was 8.85 (4.22-40.96) months. Median PFS (IQR) was 8.5 (3.93-12.55) (1L) and 8.8 (5.62-16.91) (2L) months. Disease control rate was 60% (1L) and 85% (2L). Weekly paclitaxel-cetuximab was well tolerated in 1L/2L (cutaneous-toxicity, mucositis, neuropathy; mainly Grade 1-2). No grade 4 AEs were notified in 2L. Conclusion: Weekly paclitaxel-cetuximab is an active and well tolerated therapeutical option in platinum-ineligible or after platinum regimens in R/M-SCCHN patients.

show abstract

Second-line chemotherapy in head and neck cancer: what should we expect?

Cited by 5 publications

References 32 publications

Unexpected response with palliative conventional therapy in head and neck squamous cell carcinoma after anti‐programmed death‐1 progression

Unexpected response with palliative conventional therapy in head and neck squamous cell carcinoma after anti‐programmed death‐1 progression

State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013

Real-world Data of Paclitaxel and Cetuximab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Contact Info

Product

Resources

About